Fasenra (benralizumab) (Subcutaneous)
Prior authorization policy for Fasenra (benralizumab) covering initial and renewal approval criteria, dosing/administration, allowed diagnoses, billing codes (HCPCS and NDC), concomitant therapy restrictions, and authorization duration for commercial members (non‑Medicare determinations guidance included).
No material clinical/coverage changes in this update
Coverage Summary
This policy: covers Fasenra (benralizumab) with prior authorization and specific clinical criteria for commercial members. Primary indications covered are severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). Authorization length is 365 days for initial and renewal approvals. The policy scope includes prior authorization rules, dosing/administration and billing codes (primary HCPCS code J0517), allowed diagnoses, concomitant therapy restrictions, and applies to commercial members.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.